Research
Hormonal
Participants without type 2 diabetes (T2D) achieved significantly greater weight loss than those with T2D, with a median weight loss of 11.21% vs 5.48%, P < 0.001.
Practitioners should consider diabetes status when setting weight loss expectations for patients.
StrongSupportsmedium confidence
Participants without T2D achieved significantly greater weight loss than those with T2D (11.21% vs 5.48%, P < 0.001).
Why this rating
The study is a retrospective cohort analysis with a significant sample size.
Source
Magnitude and Determinants of Weight Loss Response to GLP-1/GIP Receptor Agonists in India: A Real-World Time-to-Event Analysis
Godana Jarso et al. · Indian Journal of Endocrinology and Metabolism · 2026
DOI 10.4103/ijem.ijem_1085_25
cohort · n=150
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →